Joyce M Lee1, Ashley Eason2, Courtney Nelson3, Nayla G Kazzi4, Anne E Cowan2, Beth A Tarini5. 1. Child Health Evaluation and Research (CHEAR) Unit, Division of General Pediatrics, University of Michigan, Ann Arbor, Michigan; Division of Pediatric Endocrinology, University of Michigan, Ann Arbor, Michigan. Electronic address: joyclee@umich.edu. 2. Child Health Evaluation and Research (CHEAR) Unit, Division of General Pediatrics, University of Michigan, Ann Arbor, Michigan. 3. Child Health Evaluation and Research (CHEAR) Unit, Division of General Pediatrics, University of Michigan, Ann Arbor, Michigan; University of Toledo College of Medicine, Toledo, Ohio. 4. Child Health Evaluation and Research (CHEAR) Unit, Division of General Pediatrics, University of Michigan, Ann Arbor, Michigan; University of Michigan Medical School, Ann Arbor, Michigan. 5. Child Health Evaluation and Research (CHEAR) Unit, Division of General Pediatrics, University of Michigan, Ann Arbor, Michigan; Division of Pediatric Endocrinology, University of Michigan, Ann Arbor, Michigan.
Abstract
OBJECTIVE: To characterize pediatrician and family physician (FP) screening practices for type 2 diabetes among adolescents and to examine the impact of the 2010 American Diabetes Association (ADA) guidelines, recommending use of Hemoglobin A1c (HbA1c). METHODS: We conducted a cross-sectional mail survey of a random sample of 1,400 U.S. pediatricians and FPs and we received 604 eligible responses. Our main outcome measure was the types of tests ordered by physicians, particularly HbA1c, when presented with a hypothetical scenario. RESULTS: The overall response rate was 52% (57% for pediatricians and 48% for FPs). Fasting glucose and HbA1c were the most commonly ordered tests. Overall, at least 58% of physicians ordered HbA1c; 35% ordered HbA1c in conjunction with fasting tests; and 22% ordered HbA1c alone or with nonfasting tests. Only 38% of providers were aware of the new ADA recommended HbA1c screening guidelines. However, a majority (67%) said they would change their screening practices. In the context of the guidelines, 84% of physicians would now order HbA1c. Furthermore, there was a large increase in the proportion of physicians who would shift to using HbA1c only or with other nonfasting tests. CONCLUSIONS: When screening adolescents for type 2 diabetes, providers are more likely to order HbA1c and order fewer fasting tests in response to the new ADA guidelines. HbA1c has lower sensitivity and higher costs than other testing modalities in children, therefore increasing uptake of this test (HbA1c) in children may have implications for both detection rates and healthcare costs.
OBJECTIVE: To characterize pediatrician and family physician (FP) screening practices for type 2 diabetes among adolescents and to examine the impact of the 2010 American Diabetes Association (ADA) guidelines, recommending use of Hemoglobin A1c (HbA1c). METHODS: We conducted a cross-sectional mail survey of a random sample of 1,400 U.S. pediatricians and FPs and we received 604 eligible responses. Our main outcome measure was the types of tests ordered by physicians, particularly HbA1c, when presented with a hypothetical scenario. RESULTS: The overall response rate was 52% (57% for pediatricians and 48% for FPs). Fasting glucose and HbA1c were the most commonly ordered tests. Overall, at least 58% of physicians ordered HbA1c; 35% ordered HbA1c in conjunction with fasting tests; and 22% ordered HbA1c alone or with nonfasting tests. Only 38% of providers were aware of the new ADA recommended HbA1c screening guidelines. However, a majority (67%) said they would change their screening practices. In the context of the guidelines, 84% of physicians would now order HbA1c. Furthermore, there was a large increase in the proportion of physicians who would shift to using HbA1c only or with other nonfasting tests. CONCLUSIONS: When screening adolescents for type 2 diabetes, providers are more likely to order HbA1c and order fewer fasting tests in response to the new ADA guidelines. HbA1c has lower sensitivity and higher costs than other testing modalities in children, therefore increasing uptake of this test (HbA1c) in children may have implications for both detection rates and healthcare costs.
Authors: Erinn T Rhodes; Jonathan A Finkelstein; Richard Marshall; Carole Allen; Matthew W Gillman; David S Ludwig Journal: Ambul Pediatr Date: 2006 Mar-Apr
Authors: Tamara S Hannon; Tamara M Dugan; Chandan K Saha; Steven J McKee; Stephen M Downs; Aaron E Carroll Journal: JAMA Pediatr Date: 2017-04-01 Impact factor: 16.193
Authors: Christine L Chan; Kim McFann; Lindsey Newnes; Kristen J Nadeau; Philip S Zeitler; Megan Kelsey Journal: Pediatr Diabetes Date: 2014-03-17 Impact factor: 4.866
Authors: Arthur M Lee; Cyrelle R Fermin; Stephanie L Filipp; Matthew J Gurka; Mark D DeBoer Journal: Acta Diabetol Date: 2017-01-09 Impact factor: 4.280
Authors: Christine L Chan; Laura Pyle; Megan M Kelsey; Lindsey Newnes; Amy Baumgartner; Philip S Zeitler; Kristen J Nadeau Journal: Pediatr Diabetes Date: 2016-11-22 Impact factor: 4.866
Authors: Hala K El Mikati; Lisa Yazel-Smith; Randall W Grout; Stephen M Downs; Aaron E Carroll; Tamara S Hannon Journal: Appl Clin Inform Date: 2020-05-13 Impact factor: 2.342
Authors: Christine L Chan; Laura Pyle; Lindsey Newnes; Kristen J Nadeau; Philip S Zeitler; Megan M Kelsey Journal: J Clin Endocrinol Metab Date: 2014-12-22 Impact factor: 5.958
Authors: Mary Ellen Vajravelu; Joyce M Lee; Rachana Shah; Justine Shults; Sandra Amaral; Andrea Kelly Journal: Pediatr Diabetes Date: 2020-05-15 Impact factor: 4.866